The Society for Immunotherapy of Cancer (SITC) hosted the “Immuno-Resistance and Sequencing Symposium” during the 36th Annual Meeting & Pre-Conference Programs on November 11, 2021. Available here are the presentation slides and video from “Session III: Understanding the Biology of Therapeutic Pillars - Targeted Pathways and Future Direction,” as permitted by presenters.Program SummaryWhile immunotherapy treatments, particularly anti-PD-1 therapies, have improved outcomes for some patients, the issue of post-treatment relapse remains a large problem. The proper choice of treatment after relapse on checkpoint inhibition is, therefore, a critical issue to solve. This symposium explored the preclinical and clinical data on sequencing of immunotherapies, in order to improve patient outcomes and ensure the field of immunotherapy remains at the forefront of oncology care.
Program Organizers
To view the entire program schedule (including presenter permission to post) please click here.
Program: Immuno-Resistance and Sequencing Symposium; Session: Understanding the Biology of Therapeutic Pillars - Targeted Pathways and Future Direction; Presenter: Dimitris Skokos, PhD - Regeneron Pharmaceuticals, Inc.; Date: November 11, 202100:17:17